New York, March 02, 2015 -- Moody's Investors Service commented that the sale of Endo International plc's male urology health and prostate health businesses to Boston Scientific is credit positive for Endo. The total consideration is up to $1.65 billion, including $1.6 billion in upfront cash, and the transaction is expected to close in the third quarter of 2015. There are no immediate changes to Endo's current ratings, including the Ba3 Corporate Family Rating of Endo Luxembourg Finance I Company S.a.r.l., or the stable rating outlook.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.